Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aveo Pharmaceuticals has announced positive results from an expanded Phase I clinical trial of its lead product candidate, the novel triple VEGF receptor inhibitor AV-951, in the treatment of renal cell cancer.
Subscribe to our email newsletter
Strong activity was observed in the Phase I clinical trial consisting of 40 patients with advanced solid tumors. AV-951 was also found to be well tolerated. Of the nine patients with refractory renal cell carcinoma, all achieved either a partial response or stable disease as defined by the trial protocol, with one patient exhibiting a response lasting more than 30 months.
Based on this compelling Phase I data, Aveo has initiated a Phase II clinical trial of AV-951 in patients with metastatic renal cell carcinoma. The primary endpoints of this trial are objective response rate and percentage of patients who are progression free at 12 weeks following randomization.
AV-951 is a novel, highly potent and specific inhibitor of VEGF receptors 1, 2 and 3.
Tuan Ha-Ngoc, president and CEO of Aveo, said: “AV-951 is a highly potent VEGFR inhibitor and one of the only agents to demonstrate potent activity against all three critical VEGF receptors. As such, we believe AV-951 has the potential to be best-in-class against a validated target demonstrated to be important in multiple cancer types. Given the strong signals of activity and excellent safety profile observed in Phase I, AV-951 has the potential to be effective both as a single-agent and in combination regimens benefiting multiple tumor types.”